CClinicalTrials.gg
Status unknownNCT03481400Updated Mar 29, 2018

CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment

An interventional study of Calcitonin Gene-Related Peptide and Placebo in Migraine, sponsored by Danish Headache Center. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Danish Headache Center · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The investigators aim to investigate the incidence of migraine attacks after calcitonin gene-related peptide (CGRP) infusion in patients who have tried anti-CGRP monoclonal antibody treatment for the prevention of migraine.

Read the detailed description

Calcitonin gene-related peptide (CGRP) plays a role in migraine pathophysiology. Infusions of CGRP can trigger migraine-like attacks in migraine patients and antibodies against CGRP or the CGRP receptor significantly reduces the number of migraine days per month when administered regularly. Some patients however, do not experience migraine attack after CGRP infusion, and some do not experience migraine reduction with antibodies. The underlying mechanisms of these effects are largely unknown.

The purpose of this study is to examine CGRP-induced migraine in patients who have evaluated the efficacy of anti-CGRP monoclonal antibody treatment for migraine using a purpose-developed standardized interview. The investigators will use a double-blind, placebo-controlled crossover study design to examine migraine susceptibility to CGRP in these patients.

02

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Calcitonin gene-related peptide
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of migraine according to the international classification of headache disorders version 3-beta
  • Subject has tried anti-CGRP antibodies for migraine
  • Women of childbearing potential are on safe contraception

Exclusion criteria

Exclusion Criteria:

  • Women of childbearing potential who do not use contraception. Includes non-hysterectomized women who have not been menopausal for at least two years. Safe contraception includes condoms, intrauterine devices, p-pills, surgical sterilization or gestagen injections.
  • Daily drug intake apart from contraceptives and preventive medication for migraine.
  • Ingestion of any drug 4 half-lifes before study start apart from contraceptives.
  • Pregnant or breast-feeding women
  • Migraine on the study day or less than 48 hours before CGRP infusion.
  • A history of cardiovascular and/or cerebrovascular disease
  • Systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg on study day.
  • Systolic blood pressure \<90 mmHg and/or diastolic blood pressure \< 50 mmHg on study day.
  • A history of mental illness
  • A history of any illness or condition that is deemed relevant for participation by the investigator.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Calcitonin gene-related peptide

    Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)

    Drug: Calcitonin Gene-Related Peptide

  • Experimental
    Placebo

    Infusion with placebo (isotonic saline)

    Other: Placebo

Interventions

  • DrugCalcitonin Gene-Related Peptide

    Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)

    Also known as: CGRP

  • OtherPlacebo

    Isotonic saline

05

What researchers measure

Primary outcomes

  1. Incidence of migraine

    Incidence of migraine after CGRP infusion

    Time frame: From 0 to 12 hours after CGRP infusion

  2. Area under the curve of headache intensity

    Area under the curve of headache intensity from 0-90 min and 90 min-12 hours post infusion

    Time frame: From 0 to 90 minutes after infusion and from 90 minutes to 12 hours after infusion

Secondary outcomes

  1. Heart rate

    Heart rate (beats per minute)

    Time frame: From 0 to 90 minutes after infusion

  2. Blood pressure

    Blood pressure (millimeter of mercury)

    Time frame: From 0 to 90 minutes after infusion

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Christensen CE, Younis S, Deen M, Khan S, Ghanizada H, Ashina M. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain. 2018 Nov 8;19(1):105. doi: 10.1186/s10194-018-0927-2. PubMed 30409109 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03481400
Lead sponsor
Danish Headache Center
Responsible party
Casper Emil Christensen (MD, PhD student, Danish Headache Center) — Principal investigator
First posted
Mar 29, 2018
Start date
Jul 2016
Primary completion
Sep 2019 (estimated)
Completion
Sep 2019 (estimated)
Last update
Mar 29, 2018

Study contacts

Casper E Christensen, MD
Contact
casper.emil.christensen.03@regionh.dk
38632027
Samaira Younis, MD
Contact
samaira.younis.01@regionh.dk
38632176
Messoud Ashina, prof.
study director · Danish Headache Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion